Monopar Therapeutics (NASDAQ:MNPR) Receives Buy Rating from Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a report issued on Monday,Benzinga reports. They presently have a $100.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 84.84% from the stock’s previous close.

A number of other brokerages have also weighed in on MNPR. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. BTIG Research reissued a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Morgan Stanley started coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They set an “overweight” rating and a $115.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $54.10 on Monday. The stock has a market capitalization of $361.55 million, a P/E ratio of -29.73 and a beta of 1.58. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The firm has a 50 day moving average of $59.62 and a 200-day moving average of $70.95.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). As a group, analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the 3rd quarter worth $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the second quarter valued at about $34,000. BNP Paribas Financial Markets increased its holdings in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $65,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.